J’Onco Mentor Version 9.09 — PANCREAS PRIMARY

Desktop version. Mobile app coming.

WHAT IS J’ONCO MENTOR?LUNGBREASTHEAD & NECKPROSTATEENDOMETRIUMLIVERADRENAL GLANDKIDNEYTHYROIDBLADDERCOLON & RECTUMMELANOMA OF SKINPANCREASSTOMACHCNSHEMATOPOIETIC DISORDERSTOP CANCER SITESSTORE MANUALRADIATION GUIDESTATE REPORTABILITYICD-10-CM / SECONDARY DXODS RESOURCES

DIAGNOSIS YEAR

Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.

SEER manual—
NAACCR cycle—
Staging context—
Standards statusSelect year
No diagnosis year selected. Year-dependent schema, staging, SSDI, grade, surgery, and manual guidance should not be assumed.

INTERACTIVE PANCREAS PRIMARY-SITE SELECTOR

Realistic pancreas anatomy with labeled head, neck, body, tail, pancreatic duct, duodenum, bile duct, portal vein, common hepatic artery, celiac axis, superior mesenteric artery and superior mesenteric vein
Head C25.0Body C25.1Tail C25.2Duct C25.3Neck C25.7

Click a cyan pancreatic site marker on the realistic anatomy. Click the active marker again to deselect it. Use the dropdown for endocrine pancreas NOS, overlapping lesion, or pancreas NOS.

Selecting an additional site here adds it immediately. Diagram selections and this field stay synchronized.

SELECTED PANCREATIC SUBSITE(S)
None selected.
PRIMARY SITE CODE

—

No pancreatic site selected.

SEER coding point
Assign the code for the point of origin. Multiple selected subsites do not automatically mean C25.8. Use C25.8 only when the lesion overlaps two or more pancreatic subsites and the point of origin cannot be determined. For an islet-cell/NET tumor, use head/body/tail when the subsite is known; use C25.4 when the endocrine/islet subsite cannot be determined.

HISTOLOGY / TUMOR FAMILY

Type a code or name, or use the dropdown below. Both controls stay synchronized.

SCHEMA ROUTING

—

The current SEER EOD framework separates Pancreas (excluding neuroendocrine tumor) from Neuroendocrine Tumors of Pancreas. Choose the tumor family before using staging guidance.

Histology library: This first Pancreas build includes common histologies. The next refinement should load the full SEER Solid Tumor Rules Table 11 pancreas histology set rather than relying on a short list.

MULTIPLE PRIMARY RULES

CURRENT RULE SET

OTHER SITES

Pancreas is handled under the SEER Solid Tumor Rules — Other Sites site group for cases diagnosed 1/1/2023 forward.

WORKFLOW

  1. Establish reportability and behavior.
  2. Determine whether disease represents recurrence before applying M rules.
  3. Apply Other Sites multiple-primary rules.
  4. Apply Working Histology Determination / histology rules.

The November 2026 Solid Tumor Rules release includes recurrence-rule updates. Always use the rule set appropriate to the diagnosis year and implementation guidance.

REGIONAL LYMPH NODES — STARTER MAP

SELECTED NODES
None selected.

NEXT DIAGRAM PASS

A dedicated interactive pancreas lymph-node diagram will be added after the node groups are validated against the current SEER/AJCC schema by pancreatic subsite and tumor family.

This prevents a generic node map from implying that every regional basin applies identically to every pancreatic subsite.

AJCC STAGING SCHEMA

PATHOLOGIC STAGING CRITERIA — PANCREAS

Qualifying evidence: Qualifying pancreatic resection (for example, pancreaticoduodenectomy or distal pancreatectomy) generally supports pT. Examined regional lymph nodes support pN. Confirm the chapter appropriate to histology, especially pancreatic neuroendocrine tumors.

pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.

pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.

Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.

Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.

Pancreas AJCC / TNM Entry

Choose the applicable pancreatic tumor family, then enter T, N and M. J’Onco Mentor displays the TNM combination for abstracting support; verify the final AJCC stage group in the approved AJCC staging system for the diagnosis year.




AJCC / TNM RESULT

Schema—
T—
N—
M—

—

Final stage group requires the tumor-family-specific AJCC rules. Verify in AJCC / your approved staging application.

EOD / SUMMARY STAGE

EOD SCHEMAS

Pancreas — excluding NETNeuroendocrine Tumors of Pancreas

For NAACCR v26 / diagnosis year 2026, use the current SEER*RSA EOD v3.3 schema.

SUMMARY STAGE 2018

Keep Summary Stage coding separate from AJCC stage. The module will eventually translate documented extension/nodes/metastasis into a guided Summary Stage review without substituting for the official schema.

SSDI / GRADE

Effective for diagnosis years 2021+. Record the highest documented pretreatment CA 19-9 value to the nearest tenth when an exact value is available.

NAACCR #3942

Grade logic differs for pancreatic NETs; do not infer NET grade from generic “well differentiated/low grade” terminology when the schema requires physician G1/G2/G3 or Ki-67/mitotic-count rules.

SURGERY OF PRIMARY SITE — PANCREAS

SURGERY CODE

—

No surgery selected.

B250

Local excision

Local excision / enucleation; includes laser destruction, thermal therapy, or ablation.

B300

Partial pancreatectomy

Partial pancreatectomy, NOS; example: distal or subtotal pancreatectomy.

B350–B352

Whipple family

Pancreaticoduodenectomy; B351 pylorus-preserving; B352 with partial gastrectomy/classic Whipple.

B400

Total pancreatectomy

B600

Extended resection

Total pancreatectomy with subtotal gastrectomy and/or duodenectomy / extended pancreatoduodenectomy.

B800 / B900 / B990

Other / unknown

Pancreatectomy NOS; surgery NOS; unknown if surgery performed.

COMMON METASTATIC SITES — PANCREAS

Pancreatic cancers commonly spread to the liver, peritoneum, and lung. SEER Training also identifies bone as a hematogenous metastatic site.

COMMON

Liver

Major distant metastatic site for pancreatic primaries.

COMMON

Peritoneum

Common pattern of distant spread, including peritoneal seeding/carcinomatosis when documented.

COMMON

Lung

Common hematogenous distant site.

COMMON

Bone

Recognized hematogenous metastatic site in SEER training material.

Registrar reminder: Direct extension from pancreas into nearby structures such as duodenum, stomach, or spleen is not automatically distant metastasis. Distinguish contiguous extension from discontinuous metastatic disease.

SOURCES

2027 standards cycle: Use the 2027 SEER Program Coding and Staging Manual, Solid Tumor Rules 2027, STORE 2027, NAACCR v27 resources, Summary Stage v3.4, and the current diagnosis-year SEER*RSA/EOD schema as applicable. Historical cases may require prior-year instructions.